CTRI/2019/09/021175招募中4 期
The Effects Of Testosterone Replacement Therapy On Sexual Functions And Cardiovascular Risk Factors In Hypogonadal Men With Type 2 Diabetes
Dr Ronak Gandhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patient age between 30 -60 years with symptoms of hypogonadism using the Aging Male Symptom Scale (AMS) score >=27 or the presence of following three sexual symptoms
- •Decreased sexual interest
- •Absent or rare morning erections and
- •Erectile dysfunction
- •Patientâ??s morning (7am-9am) serum total testosterone level <12 nmol/
排除标准
- •Following patients will be excluded
- •Patient suffering from severe debilitating disease
- •History of prostate or breast cancer
- •Elevated hematocrit (PCV >48%)
- •Elevated prostate-specific antigen (PSA >4.0 ng/ml; PSA >3 with a high risk)
- •PSA increase >1.4ng/ml within any 12 month period
- •Palpable prostate nodule and induration on digital rectal examination (DRE)
- •Severe obstructive sleep apnea (OSA)
- •Severe lower urinary tract symptoms (LUTS) (International Prostate Symptom Score [IPSS] >19 )
- •Previously treated hypogonadism
- •Acute coronary event in last 6 months
- •Chronic obstructive lung disease
- •Recent use of PDE-5 inhibitors (within last 6 months)
研究者
相似试验
招募中
Unknown
Effect of testosterone replacement associated with bariatric surgery in men with obesityObesityRBR-9qks3pcHospital e Maternidade São Domingos
进行中（未招募）
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failureEUCTR2005-002607-17-DEProstrakan Pharmaceuticals Ltd520
进行中（未招募）
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes MellitusEUCTR2005-002607-17-ITSTRAKAN PHARMACEUTICALS LIMITED320
进行中（未招募）
1 期
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failureEUCTR2005-002607-17-GBProstrakan Pharmaceuticals Ltd520
进行中（未招募）
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2EUCTR2005-002607-17-BEProStrakan Ltd520